Ryman Healthcare Limited
RHCGF · OTC
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.00 | -0.05 | 0.03 |
| FCF Yield | 5.81% | 5.38% | 5.21% | 6.23% |
| EV / EBITDA | 110.70 | -12.25 | 256.80 | -574.26 |
| Quality | ||||
| ROIC | -0.09% | -0.63% | 0.18% | -0.05% |
| Gross Margin | -2.53% | -13.87% | 6.39% | 1.87% |
| Cash Conversion Ratio | -3.63 | -0.24 | 3.00 | -1.76 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.28% | 17.50% | 16.90% | 15.62% |
| Free Cash Flow Growth | -10.40% | -41.24% | -33.40% | 66.39% |
| Safety | ||||
| Net Debt / EBITDA | 44.13 | -5.99 | 117.78 | -226.94 |
| Interest Coverage | -0.18 | -0.59 | 0.37 | -0.37 |
| Efficiency | ||||
| Inventory Turnover | 30,675.82 | 32,495.77 | 182.30 | 150.47 |
| Cash Conversion Cycle | 18.95 | 16.18 | -6.40 | 142.00 |